Why Is NEOGEN CORP (NEOG) Stock Moving Today?

NEOG stock surged 22.66% to $11.53 in early trading on July 30, 2026, driven by the release of strong Q4 fiscal 2026 earnings results and the company’s updated guidance for fiscal 2027. Neogen Corporation reported revenue of $225.3 million for the quarter, exceeding estimates and showing 4.3% core revenue growth, the highest for the year. The company also raised its long-term revenue and adjusted EBITDA outlook for 2027 and reported better-than-expected adjusted earnings per share.

What Happened

Neogen’s Q4 FY2026 earnings call highlighted a strong performance across its core operations. The company reported revenue of $225.3 million, with both its food safety and life sciences segments contributing to the growth. The company also announced adjusted earnings per share of $0.09, surpassing the estimated loss of $0.07. In addition, Neogen outlined FY2027 revenue guidance of $880 million to $885 million and adjusted EBITDA of $180 million to $182 million. These figures represent a significant increase from previous expectations and reflect improved momentum in the business. The company also noted a 50% increase in R&D investment, signaling a strategic focus on innovation and long-term growth.

What The Data Shows

The stock’s performance was supported by strong earnings surprises and optimistic guidance. The company’s Q1 sales guidance of $207 million to $209 million also exceeded estimates of $204.7 million. Despite a recent trailing twelve-month revenue decline of 3.9% and a net margin of -69.9%, the positive earnings beat and forward-looking guidance have sparked investor optimism. The stock closed at $11.53, near its 52-week high of $11.43, suggesting a potential reversal in its recent trend. The market reaction indicates that investors are responding favorably to the company’s operational improvements and strategic direction.

What To Watch

The company’s full FY2027 guidance and ongoing R&D investment will be key to watch in the coming months. Additionally, the regulatory status of Zoetis’ acquisition of Neogen’s genomics business in Australia may impact future operations and market perception.